End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
125,000.00 KRW | +0.16% | +3.99% | +81.69% |
08-22 | South Korean Shares Rise After BOK Rate Hold; Yuhan Gains on FDA Approval | MT |
08-22 | Yuhan Shares Jump 4% After US FDA Approves Anti-Cancer Drug for US Markets | MT |
Fiscal Period: December | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|---|---|---|---|
Net Income | 40.01B | 193B | 103B | 95.14B | 136B | |||||
Depreciation & Amortization - CF | 54.09B | 55B | 47.16B | 38.55B | 38.47B | |||||
Amortization of Goodwill and Intangible Assets - (CF) | 4.57B | 4.79B | 5.51B | 4.47B | 6.21B | |||||
Depreciation & Amortization, Total | 58.66B | 59.78B | 52.67B | 43.02B | 44.68B | |||||
(Gain) Loss From Sale Of Asset | -7.32B | -132B | 624M | -180M | -132M | |||||
(Gain) Loss on Sale of Investments - (CF) | -877M | 2.22B | 6.64B | -2.05B | 54.48M | |||||
Asset Writedown & Restructuring Costs | 4.9B | - | 5.15B | 5.06B | 1.26B | |||||
(Income) Loss On Equity Investments - (CF) | -30.28B | -61.12B | -75.86B | -42.38B | -81.37B | |||||
Stock-Based Compensation (CF) | - | - | 689M | 464M | 339M | |||||
Provision and Write-off of Bad Debts | 351M | 1.19B | -1.42B | 2.08B | 1.33B | |||||
Other Operating Activities, Total | 64.4B | 122B | 68.86B | 108B | 50.27B | |||||
Change In Accounts Receivable | -55.42B | -61.17B | -16.92B | -37.34B | -63.42B | |||||
Change In Inventories | 56.54B | -69.27B | -26.11B | -382M | -5.4B | |||||
Change In Accounts Payable | 21.31B | 11.77B | 20.56B | -7.81B | 44.51B | |||||
Change in Other Net Operating Assets | -86.28B | -37.32B | -38.48B | -64.52B | 15.91B | |||||
Cash from Operations | 65.99B | 28.83B | 99B | 99.53B | 144B | |||||
Capital Expenditure | -42.76B | -51.45B | -46.15B | -65.8B | -161B | |||||
Sale of Property, Plant, and Equipment | 325M | 372M | 178M | 23.91M | 181M | |||||
Divestitures | -70M | - | - | 1.94B | 12.56B | |||||
Sale (Purchase) of Intangible assets | -3.97B | -33.23B | -35.12B | -36.08B | -42.42B | |||||
Investment in Marketable and Equity Securities, Total | 84.29B | -43.5B | -146B | 129B | -53.72B | |||||
Net (Increase) Decrease in Loans Originated / Sold - Investing | 67.41M | -297M | 99M | 138M | -83M | |||||
Other Investing Activities, Total | -6.27B | 186B | 59.8B | -13.49B | 45.74B | |||||
Cash from Investing | 31.6B | 57.59B | -167B | 15.62B | -199B | |||||
Short Term Debt Issued, Total | 14.5B | 33.5B | 27B | - | 59.5B | |||||
Long-Term Debt Issued, Total | - | 4.4B | 1.9B | - | 58.2B | |||||
Total Debt Issued | 14.5B | 37.9B | 28.9B | - | 118B | |||||
Short Term Debt Repaid, Total | -871M | - | -6.5B | -5B | -2.12B | |||||
Long-Term Debt Repaid, Total | -49.27B | -8.58B | -23.78B | -25.04B | -29.67B | |||||
Total Debt Repaid | -50.14B | -8.58B | -30.28B | -30.04B | -31.79B | |||||
Issuance of Common Stock | - | - | - | - | - | |||||
Repurchase of Common Stock | -8.4B | -3.12B | -16.42B | -16.46B | -7.46B | |||||
Common Dividends Paid | -22.91B | -23.78B | -24.94B | -26.08B | -27.27B | |||||
Common & Preferred Stock Dividends Paid | -22.91B | -23.78B | -24.94B | -26.08B | -27.27B | |||||
Other Financing Activities, Total | -57.99M | 9.27B | 6.21B | 7.04B | 12.07B | |||||
Cash from Financing | -67.01B | 11.69B | -36.53B | -65.54B | 63.25B | |||||
Foreign Exchange Rate Adjustments | 2.34B | -18.84B | 4.77B | -10.16B | -1.92B | |||||
Miscellaneous Cash Flow Adjustments | - | - | - | - | - | |||||
Net Change in Cash | 32.92B | 79.28B | -99.9B | 39.45B | 6.22B | |||||
Supplemental Items | ||||||||||
Cash Interest Paid | 3.1B | 2.48B | 2.71B | 3.11B | 4.3B | |||||
Cash Income Tax Paid (Refund) | 35.59B | 27.96B | 39.16B | 66.22B | 32.9B | |||||
Levered Free Cash Flow | 17.69B | -78.26B | -7.04B | -85.73B | -132B | |||||
Unlevered Free Cash Flow | 19.63B | -76.56B | -5.2B | -83.56B | -128B | |||||
Change In Net Working Capital | 132M | 105B | 7.66B | 47.56B | 4.37B | |||||
Net Debt Issued / Repaid | -35.64B | 29.32B | -1.38B | -30.04B | 85.91B |